HEMOSTASIS CONNECT’s Post

Training burden can be extremely high for clinical trial raters. In this 2-min video, Dr. Pam Ventola outlines a methodology called a Rater Academy that can be adopted to reduce the burden on sites and raters while maintaining quality data outcomes. In this model, raters certify at a gold standard one time and then participate across multiple trials in a clinical program without the need for recertification. Check out the efficiency data presented in this video 👉 https://lnkd.in/eb3jaywn

We cannot afford to get the #EUPhamaLegislation wrong: we risk losing 45 #raredisease medicines in Europe between 2020 and 2035, impacting around 1.5 million European rare disease patients. As discussions at the Council progress, we look forward to continuing the dialogue on how we can define a legislation that will support rather than hinder the research, development and manufacture of new treatments in the EU. #WeWontRest #EURareDiseases

September is AFib Awareness Month! Learn more about how to manage Atrial Fibrillation with this free SHARED Decision-Making Guide from National Forum for Heart Disease & Stroke Prevention: natforum.org/AFIB_Guide #AFib #HeartHealth #StrokePrevention #PatientEmpowerment #AFibAwarenessMonth

Engaging with patient associations is crucial for pharma companies since it offers a unique opportunity to understand patient needs to better improve treatments, ultimately leading to a healthier future for everyone.   For Mark Bell, General Manager UK & Ireland, and his team, dedication to supporting patient groups has been a cornerstone of their efforts. By actively engaging with these groups, they have gained important insights from patients living with rare diseases and their everyday life with the disease. This interaction has been instrumental in shaping Immedica’s approach towards patient-centric solutions.   Read more about Immedica and what we do for those living with rare diseases. www.immedica.com   #immedica #immedicapharma #rarediseases #patientadvocacy

Patient insights are not “nice to have”. They are integral part of our daily operation, fulfilling our Commitment to patients and caregivers. Elevating the voice of patient community, facilitating Patient Associations’ visibility, actively listening to their needs and responding with meaningful initiatives are the core elements of our strategic approach. Today Athanasios Pallidis, Vice President of LDL Greece PAG shared his perspective during Novartis Hellas hybrid scientific event on Dyslipidemia, in Thessaloniki, highlighting the importance of shared decision making in disease management. #patientadvocacy #patientinsights #patientempowerment

Through the MPE Navigator, myeloma and AL amyloidosis patients can search for clinical trials in Europe. You can find trials aligned with your requirements, whether it is a particular hospital or a specific disease stage. Visit the MPE Navigator: https://lnkd.in/dDRHsv2Z #EuropeanMyelomaDay #LearnShareChange #MPENavigator

Looking for comprehensive drug and disease information to support clinical decision-making? Discover the power of DynaMedex®. 💡 From medication safety to disease management, #DynaMedex offers evidence-based resources that can streamline your workflow and support confident decision-making at the point of care. 🔗 Learn more: https://lnkd.in/gJyBiy3T #EvidenceBasedMedicine #ClinicalDecisionSupport #HealthcareInnovation

🌍 Today, on World Patient Safety Day, the World Orphan Drug Congress joins the global call to prioritise safety in healthcare, particularly for patients facing rare diseases. This year, the focus is on enhancing diagnostic safety to ensure every patient receives timely and accurate diagnoses. Misdiagnosis or delayed diagnosis can greatly impact treatment outcomes for rare disease patients, making this mission even more critical. Let’s come together to: 1️⃣ Empower patients to be proactive in their diagnosis. 2️⃣ Support healthcare professionals in maintaining excellence in diagnostic practices. 3️⃣ Leverage innovation and technology to improve diagnostic accuracy. Together, we can create safer, more reliable healthcare systems 💙. For more details on how to get involved, visit the WHO’s World Patient Safety Day 2024 page. #WorldPatientSafetyDay #PatientSafety #OrphanDrugs #RareDisease #DiagnosticExcellence #WODC #WorldOrphanDrugCongress

Today is World Patient Safety Day🌐, and it serves as an important reminder of the collective responsibility we have across the life sciences industry. Whether you're working in pharma, biotech, healthcare, or research, patient safety must always be at the heart of what we do. In the orphan drug and rare disease space, ensuring accurate diagnoses and safe treatment protocols is particularly crucial. Many patients face long journeys towards diagnosis, making safety in healthcare delivery even more vital. By fostering collaboration, promoting innovation, and encouraging best practices, we can make strides in improving patient outcomes. View the WHO recommended best practices below! #WorldPatientSafetyDay #LifeSciences #PatientFirst #OrphanDrugs #PatientSafety #HealthcareInnovation

Want to feel more confident managing AFib? Check out the National Forum for Heart Disease & Stroke Prevention's shared decision-making guide at natforum.org/AFIB_Guide. #AFib #HeartHealth #StrokePrevention #PatientEmpowerment #AFibAwarenessMonth